Abstract
Synopsis
Analysis of Intas's corporate history, corporate relationships, biosimilars development pipeline, and Datamonitor's evaluation of the company's strategy and key strengths, weaknesses, opportunities and threats.
Description
INTRODUCTION
This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.
FEATURES AND BENEFITS
- Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.
- Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.
HIGHLIGHTS
- Having entered the biosimilars market in 2004, Intas currently markets four biosimilar products in India and other semi-regulated markets of Africa, Asia Pacific, and Latin America.
- The company has had an active strategy of expansion overseas, but has now shifted to focus on targeting the domestic market due to lower than expected returns from biosimilars and the requirement for high levels of investment in order to penetrate major markets.
YOUR KEY QUESTIONS ANSWERED
- See where Intas's portfolio of four marketed biosimilar products fit in to its wider strategy
- Assess the prospects for Intas's biosimilars pipeline, which includes the monoclonal antibody rituximab in Phase III development in India
Table of Contents
ABOUT THIS REPORT
- Chapter structure
- Strategic insight
- Product analysis
- Corporate structure
- Data sourcing
- Definition of biosimilars and copy biologics
- PharmaVitae Explorer database
EXECUTIVE SUMMARY
- Key findings
- Intas biosimilars overview
- Intas biosimilars infrastructure
STRATEGIC INSIGHT
- Intas biosimilars SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Biosimilars account for only a small part of Intas's business
- Synergies with oncology generics and plasma protein products
- Return to focus on the domestic market
- Biosimilars face intense competition in India
KEY PRODUCTS
- Intas's biosimilar portfolio
- Epofit/Erykine (epoetin alfa)
- Market overview
- Key competitors
- Neukine and Neupeg (filgrastim and pegfilgrastim)
- Market overview
- Key competitors
- Intalfa (interferon alfa-2b)
- Market overview
- Interferon alfa market size
- Key competitors
CORPORATE STRUCTURE
- Background
- Company structure
- Astron Research
- Accord Healthcare
- Intas Medi Devices
- Intas Biopharmaceuticals
- Deals and alliances
APPENDIX
- References
- Exchange rates
TABLES
- Table: Intas biosimilars development and marketing capabilities
- Table: Intas's biosimilar brands price comparison with reference brands, 2012
- Table: Intas's biosimilar/copy-biologic portfolio
- Table: Sales of key epoetin brands in the seven major markets ($m), 2011-16
- Table: Pipeline and marketed biosimilar/copy-biologic epoetin drugs, 2012
- Table: Sales of key filgrastim and pegfilgrastim brands in the seven major markets ($m), 2011-16
- Table: Pipeline and marketed biosimilar/copy-biologic filgrastim and pegfilgrastim drugs
- Table: Sales of key interferon alfa brands in the seven major markets ($m), 2011-16
- Table: Pipeline and marketed biosimilar/copy-biologic interferon alfa drugs
- Table: Intas deal activity and biosimilar deals, 2010-12
- Table: Exchange rates, 2012
FIGURES
- Figure: The PharmaVitae Explorer
- Figure: Intas biosimilars overview
- Figure: Intas SWOT analysis
- Figure: Proportion of government and private health expenditure versus personal disposable income in India and other major markets, 2009
- Figure: Intas total company revenues showing share attributed to biopharmaceuticals, 2005-11
- Figure: Synergies provided by overlap within Intas Biopharmaceuticals
- Figure: Intas Pharmaceuticals sales, by geography, FY2008-10
- Figure: Intas biopharmaceuticals' revenues, FY2008-FY2012
- Figure: Intas Pharmaceuticals' revenues, FY2008-FY2012
- Figure: Intas Pharmaceuticals' revenues, by geography, FY2011
- Figure: Intas Pharmaceuticals' subsidiaries, 2012
